Compare SKYT & PHAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SKYT | PHAT |
|---|---|---|
| Founded | 1991 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 939.6M | 942.6M |
| IPO Year | 2021 | 2019 |
| Metric | SKYT | PHAT |
|---|---|---|
| Price | $16.36 | $15.39 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 6 |
| Target Price | ★ $19.40 | $17.33 |
| AVG Volume (30 Days) | ★ 1.6M | 785.4K |
| Earning Date | 11-05-2025 | 10-30-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 2.62 | N/A |
| Revenue | ★ $346,587,000.00 | $147,190,000.00 |
| Revenue This Year | $28.48 | $218.59 |
| Revenue Next Year | $41.29 | $84.38 |
| P/E Ratio | $6.24 | ★ N/A |
| Revenue Growth | 0.19 | ★ 460.30 |
| 52 Week Low | $5.67 | $2.21 |
| 52 Week High | $24.23 | $16.45 |
| Indicator | SKYT | PHAT |
|---|---|---|
| Relative Strength Index (RSI) | 46.23 | 61.22 |
| Support Level | $17.78 | $14.24 |
| Resistance Level | $20.88 | $16.45 |
| Average True Range (ATR) | 1.39 | 0.76 |
| MACD | -0.03 | -0.05 |
| Stochastic Oscillator | 31.31 | 52.79 |
SkyWater Technology Inc is a U.S.-based, independent, pure-play technology foundry that offers semiconductor development and manufacturing services from its fabrication facilities. In its technology as a service model, it leverages a foundation of proprietary technology, engineering to co-develop process technology intellectual property (IP) with its customers that enable disruptive concepts through its Technology Services for diverse microelectronics (integrated circuits) and related micro- and nanotechnology applications. It focuses on serving diversified, high-growth, end users in numerous vertical markets, including computation, aerospace and defense (A&D), automotive and transportation, bio-health, and industrial.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.